ArticleJournal of the American Heart Association2025
Metabolomic Biomarkers Are Independently Associated With Secondary Adverse Cardiovascular Events in Patients With Coronary Artery Disease.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Reduced serum acetyl-L-carnitine is associated with hypertensive disorders in women with gestational diabetes mellitus: a multi-omics study.Cardiovascular diabetology · 2026Article
- Gut microbiota-derived metabolites in cardiovascular disease: mechanisms, disease-specific roles, and translational opportunities.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThis study evaluated the potential of plasma metabolites as novel biomarkers for secondary major adverse cardiovascular event (MACE) development and risk prediction in patients with coronary artery disease.
methodsWe analyzed data from 10 175 UKB (UK Biobank) participants with coronary artery disease and metabolites (n=249) measured through nuclear magnetic resonance at baseline. Cross-validated elastic net regression models were used in the training cohort (n=7122) to select metabolites to be included in the metabolomic risk score (MRS). Hazard ratios (HRs) were estimated to examine the association between MRS and MACEs (composite of nonfatal myocardial infarction, ischemic stroke, and cardiovascular death) in the testing cohort (n=3053). Predictive performance of MRS was evaluated with C-index and calibration plots.
resultsOver a median follow-up of 10 years, 1624 (16%) MACEs occurred. Elastic net regression identified 26 metabolites for construction of the MRS. Participants in the highest 20% of the MRS had significantly increased risk of MACEs (HR, 2.19 [95% CI, 1.61-2.99]) and cardiovascular death (HR, 3.69 [95% CI, 2.35-5.78]), compared with the lowest 20%, after adjusting for traditional risk factors. Adding MRS to a traditional risk factor model modestly improved the 10-year MACE prediction (ΔC-index: 0.012 [95% CI, -0.003 to 0.025]); calibration slopes (0.91 [95% CI, 0.79-1.03] versus 0.88 [95% CI, 0.74-1.02]).
conclusionsMetabolomic biomarkers are independently associated with and predict MACEs, particularly cardiovascular death, in middle-aged individuals with coronary artery disease, providing valuable insights into the biological pathways underlying MACEs in high-risk populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.